Drug resistance and the role of combination chemotherapy in improving patient outcomes.
about
Tumor Heterogeneity, Single-Cell Sequencing, and Drug ResistanceExosomes-mediate microRNAs transfer in breast cancer chemoresistance regulationChemotherapeutic Drugs Interfere with Gene Delivery Mediated by Chitosan-Graft-Poly(ethylenimine)Modeling and optimization of nanoemulsion containing Sorafenib for cancer treatment by response surface methodology.Plasmid transfer of plasminogen K1-5 reduces subcutaneous hepatoma growth by affecting inflammatory factorsSingle-cell Western blotting after whole-cell imaging to assess cancer chemotherapeutic response.Design and evaluation of a peptide-based immunotoxin for breast cancer therapeutics.APC selectively mediates response to chemotherapeutic agents in breast cancer.Developing multi-target therapeutics to fine-tune the evolutionary dynamics of the cancer ecosystem.Bisindole-PBD regulates breast cancer cell proliferation via SIRT-p53 axis.Effective combination treatment of lung cancer cells by single vehicular delivery of siRNA and different anticancer drugs.Second-generation proteasome inhibitor carfilzomib sensitizes neuroblastoma cells to doxorubicin-induced apoptosis.Intracellular STING inactivation sensitizes breast cancer cells to genotoxic agents.Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents.Creating chemotherapeutic-resistant breast cancer cell lines: advances and future perspectives.Nano-based strategies to overcome p-glycoprotein-mediated drug resistance.Natural Polyphenols in Cancer Chemoresistance.Application of Combination High-Throughput Phenotypic Screening and Target Identification Methods for the Discovery of Natural Product-Based Combination Drugs.A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4).Loss of WAVE3 sensitizes triple-negative breast cancers to chemotherapeutics by inhibiting the STAT-HIF-1α-mediated angiogenesis.Newcastle disease virus, rituximab, and doxorubicin combination as anti-hematological malignancy therapy.Combination effect of therapies targeting the PI3K- and AR-signaling pathways in prostate cancer.Crizotinib, a MET inhibitor, inhibits growth, migration, and invasion of breast cancer cells in vitro and synergizes with chemotherapeutic agents.Balaglitazone reverses P-glycoprotein-mediated multidrug resistance via upregulation of PTEN in a PPARγ-dependent manner in leukemia cells.BAG3 Overexpression and Cytoprotective Autophagy Mediate Apoptosis Resistance in Chemoresistant Breast Cancer Cells.Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers.Intrinsic and induced drug resistance mechanisms: in silico investigations at the cellular and tissue scales.A Metabolomic Approach to Predict Breast Cancer Behavior and Chemotherapy Response.Selection of P-Glycoprotein Inhibitor and Formulation of Combinational Nanoformulation Containing Selected Agent Curcumin and DOX for Reversal of Resistance in K562 Cells.Induction of apoptosis and suppression of tumor growth by Nur77-derived Bcl-2 converting peptide in chemoresistant lung cancer cells.Clinical significance of miRNA - 106a in non-small cell lung cancer patients who received cisplatin combined with gemcitabine chemotherapy.Genetics and Expression Profile of the Tubulin Gene Superfamily in Breast Cancer Subtypes and Its Relation to Taxane Resistance
P2860
Q26744341-18B4C4AC-7182-4793-A9FD-8FA310733E2DQ28066991-D9E06FE2-DB7C-48D7-9BA1-43361B62C679Q28547144-3E957E8F-A5D6-4021-8226-F09C3D108E8BQ30361130-E31998C3-9742-447D-9B45-30E12FEAF622Q33667160-435E5AEE-CC41-4F26-96A4-1A5BC72510A1Q34379843-7FA1ADC4-B355-4F5B-9A08-3A307C60EA74Q35244073-87221031-8A0F-4BB0-B147-257276C087FFQ35655334-A9E9CD1C-65FF-4C03-A951-983476F77D4BQ36097745-52EBD235-D799-4846-A687-8F9349A9327CQ36838991-BB33E3EF-D9C9-4506-A278-577D8750520EQ37265705-C8491A49-86E5-476E-99D4-1956E6A66FFAQ37689041-791A6078-3C28-47D7-82B9-D249578A9219Q37718357-E900C962-047D-44AB-9844-BB71467238EDQ38695528-E0DA04DE-D26A-497E-B6F6-BE6F9413AFD9Q38779433-64ABE93F-B301-4309-9264-74F14448F0AEQ38856533-965EE1EA-4A7F-4447-86D9-EC1CB1D106C9Q38883165-40E6764D-0BE1-433E-B2BD-C11F092CAB09Q39311040-30CE6C16-377D-41DD-A50D-9C2BD6B5D343Q40417182-CA595DFC-2351-4533-9119-3647556A2DE3Q40492761-94DC72B3-6FD9-4D8C-843A-45584332971EQ40600575-DDC3D7C1-64F0-4784-AF72-BF9DF871DECDQ41906245-C13AC955-E930-451E-8450-C5A501DA8A15Q42373819-C69E730E-7D11-4E5A-B2B4-3A28135871C3Q47697799-E6E50AC4-4E18-44CB-9E44-673FAFD4A6EBQ49806879-73FCC819-ABA7-41B3-AED1-D2224F0B2060Q50847750-D5FA52C5-CD06-42E9-9229-5B7F4AA7DEB7Q51833938-C0F12D4D-7916-4FB1-96E1-211AE4C15293Q52692110-4006474A-7314-4BC5-97E6-5B8F19D4CBF4Q53739113-78F212BC-B5CE-49DE-9C56-F431E41F8F90Q55383652-CDFCBDC7-861B-4DE8-B041-6C141F8983A5Q55399368-8DCB7EB5-A621-4A77-8D3F-276ED670EA53Q58766772-54571EEC-781E-410A-9983-79ACCDA0CD2E
P2860
Drug resistance and the role of combination chemotherapy in improving patient outcomes.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Drug resistance and the role of combination chemotherapy in improving patient outcomes.
@en
type
label
Drug resistance and the role of combination chemotherapy in improving patient outcomes.
@en
prefLabel
Drug resistance and the role of combination chemotherapy in improving patient outcomes.
@en
P2860
P356
P1476
Drug resistance and the role of combination chemotherapy in improving patient outcomes.
@en
P2093
Denise A Yardley
P2860
P304
P356
10.1155/2013/137414
P577
2013-06-24T00:00:00Z